CMO for AVXL is a big job. He is going to be in the middle of the AI-Biomarker thrust which is critical to A2-73 trails and other AVXL compounds. CNS diseases have been in the shadows for too long. IMO, when the Biomarker analysis capability is validated for each indication the gloves are off. Treatment/Knowledge growth will be exponential.